Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI

Richard C. Reichman; Nizar Tejani; John L. Lambert; Joanne Strussenberg; William Bonnez; Benjamin Blumberg; Leon Epstein; Raphael Dolin

doi:10.1016/0166-3542(93)90071-P

Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI

Richard C. Reichman^*, Nizar Tejani, John L. Lambert, Joanne Strussenberg, William Bonnez, Benjamin Blumberg, Leon Epstein, Raphael Dolin

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Thirty HIV isolates, obtained from 15 patients before and after receiving single drug therapy with didanosine (ddI), were examined for sensitivity to ddI and zidovudine (ZDV) using a peripheral blood mononuclear leukocyte (PBML)-based assay. Fourteen of the patients had ARC, one had AIDS and 12 had received previous therapy with ZDV. After a median of 1 year of ddI therapy, isolates were significantly less sensitive to ddI than were isolates obtained prior to therapy (P = 0.03). A decrease in ddI sensitivity was observed in ten of the 15 isolate pairs. In contrast to ddI susceptibilities, sensitivity to ZDV increased over the same period of time (P = 0.03). Additional isolates were obtained from four patients who received ddI monotherapy for 2 years. Three of these isolates demonstrated no change in ddI sensitivity compared to baseline. No correlation could be made in this study between development of decreased ddI sensitivity and serum p24 levels, CD4 counts, or clinical outcome. Decreased ddI sensitivity occurs frequently among HIV isolates obtained from long-term recipients of ddI. This decreased sensitivity is modest in degree and is of unknown clinical significance.

Original language	English (US)
Pages (from-to)	267-277
Number of pages	11
Journal	Antiviral Research
Volume	20
Issue number	4
DOIs	https://doi.org/10.1016/0166-3542(93)90071-P
State	Published - Apr 1993

Funding

This work was supported by AI-27658 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, and by a grant from Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-ingford, CT.

Keywords

Didanosine (ddI)
HIV resistance
Zidovudine (ZDV)

ASJC Scopus subject areas

Pharmacology
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0166-3542(93)90071-P

Cite this

@article{fccefc4be30e4c90ac861865df508092,

title = "Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI",

abstract = "Thirty HIV isolates, obtained from 15 patients before and after receiving single drug therapy with didanosine (ddI), were examined for sensitivity to ddI and zidovudine (ZDV) using a peripheral blood mononuclear leukocyte (PBML)-based assay. Fourteen of the patients had ARC, one had AIDS and 12 had received previous therapy with ZDV. After a median of 1 year of ddI therapy, isolates were significantly less sensitive to ddI than were isolates obtained prior to therapy (P = 0.03). A decrease in ddI sensitivity was observed in ten of the 15 isolate pairs. In contrast to ddI susceptibilities, sensitivity to ZDV increased over the same period of time (P = 0.03). Additional isolates were obtained from four patients who received ddI monotherapy for 2 years. Three of these isolates demonstrated no change in ddI sensitivity compared to baseline. No correlation could be made in this study between development of decreased ddI sensitivity and serum p24 levels, CD4 counts, or clinical outcome. Decreased ddI sensitivity occurs frequently among HIV isolates obtained from long-term recipients of ddI. This decreased sensitivity is modest in degree and is of unknown clinical significance.",

keywords = "Didanosine (ddI), HIV resistance, Zidovudine (ZDV)",

author = "Reichman, {Richard C.} and Nizar Tejani and Lambert, {John L.} and Joanne Strussenberg and William Bonnez and Benjamin Blumberg and Leon Epstein and Raphael Dolin",

note = "Funding Information: This work was supported by AI-27658 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, and by a grant from Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-ingford, CT.",

year = "1993",

month = apr,

doi = "10.1016/0166-3542(93)90071-P",

language = "English (US)",

volume = "20",

pages = "267--277",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI

AU - Reichman, Richard C.

AU - Tejani, Nizar

AU - Lambert, John L.

AU - Strussenberg, Joanne

AU - Bonnez, William

AU - Blumberg, Benjamin

AU - Epstein, Leon

AU - Dolin, Raphael

N1 - Funding Information: This work was supported by AI-27658 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, and by a grant from Bristol-Myers Squibb Pharmaceutical Research Institute, Wall-ingford, CT.

PY - 1993/4

Y1 - 1993/4

N2 - Thirty HIV isolates, obtained from 15 patients before and after receiving single drug therapy with didanosine (ddI), were examined for sensitivity to ddI and zidovudine (ZDV) using a peripheral blood mononuclear leukocyte (PBML)-based assay. Fourteen of the patients had ARC, one had AIDS and 12 had received previous therapy with ZDV. After a median of 1 year of ddI therapy, isolates were significantly less sensitive to ddI than were isolates obtained prior to therapy (P = 0.03). A decrease in ddI sensitivity was observed in ten of the 15 isolate pairs. In contrast to ddI susceptibilities, sensitivity to ZDV increased over the same period of time (P = 0.03). Additional isolates were obtained from four patients who received ddI monotherapy for 2 years. Three of these isolates demonstrated no change in ddI sensitivity compared to baseline. No correlation could be made in this study between development of decreased ddI sensitivity and serum p24 levels, CD4 counts, or clinical outcome. Decreased ddI sensitivity occurs frequently among HIV isolates obtained from long-term recipients of ddI. This decreased sensitivity is modest in degree and is of unknown clinical significance.

AB - Thirty HIV isolates, obtained from 15 patients before and after receiving single drug therapy with didanosine (ddI), were examined for sensitivity to ddI and zidovudine (ZDV) using a peripheral blood mononuclear leukocyte (PBML)-based assay. Fourteen of the patients had ARC, one had AIDS and 12 had received previous therapy with ZDV. After a median of 1 year of ddI therapy, isolates were significantly less sensitive to ddI than were isolates obtained prior to therapy (P = 0.03). A decrease in ddI sensitivity was observed in ten of the 15 isolate pairs. In contrast to ddI susceptibilities, sensitivity to ZDV increased over the same period of time (P = 0.03). Additional isolates were obtained from four patients who received ddI monotherapy for 2 years. Three of these isolates demonstrated no change in ddI sensitivity compared to baseline. No correlation could be made in this study between development of decreased ddI sensitivity and serum p24 levels, CD4 counts, or clinical outcome. Decreased ddI sensitivity occurs frequently among HIV isolates obtained from long-term recipients of ddI. This decreased sensitivity is modest in degree and is of unknown clinical significance.

KW - Didanosine (ddI)

KW - HIV resistance

KW - Zidovudine (ZDV)

UR - http://www.scopus.com/inward/record.url?scp=0027511647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027511647&partnerID=8YFLogxK

U2 - 10.1016/0166-3542(93)90071-P

DO - 10.1016/0166-3542(93)90071-P

M3 - Article

C2 - 8097906

AN - SCOPUS:0027511647

SN - 0166-3542

VL - 20

SP - 267

EP - 277

JO - Antiviral Research

JF - Antiviral Research

IS - 4

ER -

Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this